About UCSF Search UCSF UCSF Medical Center

Mack Roach III, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
roach_mack

Professor and Chair, Department of Radiation Oncology, and Professor, Department of Urology, UCSF

Phone: (415) 353-9807 (appts)
Box 1708, UCSF
San Francisco, CA 94143-1708

View on UCSF Profiles

Additional Websites


Education

Morehouse College, Atlanta, GA, BS, 1975, Physics
Stanford University School of Medicine, Stanford,CA, MD, 1979, Medicine
University of California San Francisco, Fellow, 1981-83, Med Oncology
Stanford University School of Medicine, Stanford,CA, Resident, 1984-87, Radiation Oncology


Professional Experience

  • 1987-1988
    Acting Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
  • 1988-1990
    Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
  • 1990-1994
    Assistant Professor, Department of Radiation Oncology, UCSF
  • 1994-2000
    Associate Professor, Department of Radiation Oncology, UCSF
  • 2000-present
    Professor, Department of Radiation Oncology & Urology, UCSF
  • 2003-2007
    Vice Chair, Department of Radiation Oncology, UCSF
  • 2006-2007
    Interim Chair, Department of Radiation Oncology
  • 2007-present
    Chair, Department of Radiation Oncology

Honors & Awards

  • 1980-1981
    Outstanding Intern of the Year (Charles R. Drew Award)
  • 1981-1982
    Fellow of the American Cancer Society
  • 1994
    UCSF Health Net Wellness Award
  • 1994-1997
    American Cancer Society Career Development Award
  • 1996-97; 1997-98; 2001-02
    "The Best Doctors in America"
  • 2002
    Fellow, American College of Radiology
  • 2002-05
    President, John Hale Medical Society
  • 2005
    10 Most Influential African Americans in the Bay Area (Healthcare)

Selected Publications

  1. Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun; 11(6):308-23.
    View on PubMed
  2. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May 1; 12(5):686-718.
    View on PubMed
  3. Roach M. Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014 Apr; 28(4):297-8.
    View on PubMed
  4. Roach M. Radical prostatectomy v radiation: only a randomised trial can provide the answer. BMJ. 2014; 348:g2266.
    View on PubMed
  5. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
    View on PubMed
  6. Roach M. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014 Jun 1; 120(11):1620-9.
    View on PubMed
  7. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9(1):42.
    View on PubMed
  8. Qi P, Pouliot J, Roach M, Xia P. Offline multiple adaptive planning strategy for concurrent irradiation of the prostate and pelvic lymph nodes. Med Phys. 2014 Feb; 41(2):021704.
    View on PubMed
  9. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8.
    View on PubMed
  10. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 1; 11(12):1471-9.
    View on PubMed
  11. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
    View on PubMed
  12. Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys. 2013; 14(5):162-72.
    View on PubMed
  13. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early salvage radiotherapy following radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1034-43.
    View on PubMed
  14. Valicenti RK, Thompson I, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M, Faraday MM. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5):822-8.
    View on PubMed
  15. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug; 190(2):441-9.
    View on PubMed
  16. Pan L, Baek S, Edmonds PR, Roach M, Wolkov H, Shah S, Pollack A, Hammond ME, Dicker AP. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol. 2013; 8:100.
    View on PubMed
  17. Kaidar-Person O, Roach M, Créhange G. Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):600-5.
    View on PubMed
  18. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 1; 119(11):1999-2004.
    View on PubMed
  19. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
    View on PubMed
  20. Chang AJ, Roach M. Cautious optimism for extreme dose escalation in prostate cancer. Eur Urol. 2013 Dec; 64(6):939-40.
    View on PubMed

Go to UCSF Profiles, powered by CTSI